Synvisc-One Arthritis Syringes Contamination Recall

A recall has been announced for Synvisc-One arthritis syringes because of possible microbial contamination that could result in patient infections.

Synvisc-One Lawsuit

The attorneys at Bernstein Liebhard LLP have launched an investigation into the Synvisc-One arthritis syringe recall. You may be entitled to compensation if you or someone you love experienced adverse events possibly associated with a contaminated Synvisc-One syringe, including:

  • Knee pain
  • Infection
  • Swelling
  • Trouble walking
  • Heat or redness
  • Fluid build-up in or around knee

To learn more about filing a Synvisc-One arthritis syringe lawsuit, please contact our office today by calling (888) 994-5118.

What is the Synvisc-One Syringe?

Synvisc-One (hylan G-F 20) is a hyaluronic acid injection manufactured by Sanofi Genzyme. It is indicated to relieve osteoarthritis knee pain in patients who have been unable to obtain adequate relief from diet, exercise and over-the-counter pain medications.

The Synvisc-One gel is made from a substance called hyaluronan, which is derived from chicken combs. Hyaluronan is also found in the human body’s synovial fluid, which occurs in large amounts in the joints.  Synovial fluid acts like a lubricant and a shock absorber, allowing the knee to function normally.

The Synvisc-One injection is administered directly into the knee by a doctor. A single dose can provide up to 6 months of knee pain relief.

Synvisc-One Knee Injection Recall

Sanofi Genentech announced a recall for a single lot of Synvisc-One arthritis syringes in December 2017, after an ongoing investigation revealed the presence of microbial contamination. A contaminated syringe could cause infections in both immunocompromised and immunocompetent patients.

The recalled lot (number 7RSL021) contained about 18,000 Synvisc-One syringes. Product from that lot was distributed throughout the U.S. from October 25, 2017 through November 7, 2017

The Synvisc-One recall was initiated after syringes from Lot 7RSL021 were associated with a “surge” of adverse events. However, Sanofi maintains that the reported side effects were “consistent with documented adverse events in the product label.” So far, no deaths have been linked to the Synvisc-One arthritis syringe recall.

It’s not clear how the syringes became contaminated. Doctors and pharmacies with unused Synvisc-One syringes from the recalled lot  have been urged to return them to Sanofi Genzyme to avoid any further problems.

Have Questions About the Synvisc-One Arthritis Syringe Recall? Our Attorneys Can Help.

Individuals who suffered side effects and complications potentially associated with the Synvisc-One arthritis syringe recall may be entitled to compensation all of their injury-related damages, including:

  • Medical bills
  • Lost wages
  • Pain and suffering
  • Emotional distress
  • Disability
  • More

To learn more about filing a Synvisc-One lawsuit, please fill out our online form or call (888) 994-5118 to obtain a free, no-obligation legal review.

  1. Sanofi Genzyme (2017) VOLUNTARY RECALL OF SYNVISC-ONE LOT 7RSL021
  2. Boston Globe (2017 Sanofi Genzyme issues recall for contaminated arthritis gel
Last Modified: January 17, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content